Refine
Year of publication
Document Type
- Article (106)
- Preprint (12)
- Conference Proceeding (5)
- Book (3)
Has Fulltext
- yes (126)
Is part of the Bibliography
- no (126)
Keywords
- Mammakarzinom (12)
- breast cancer (12)
- Behandlung (8)
- Metastasen (8)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Risiko (4)
- risk (4)
- trials (4)
- metastatic (3)
- Alpelisib (2)
- Atezolizumab (2)
- Biomarkers (2)
- CV9202 (2)
- Diagnostik (2)
- Früherkennung (2)
- Healthy adults (2)
- Katherine (2)
- Lokalrezidiv (2)
- NMR spectroscopy (2)
- Nachsorge (2)
- Non-small cell lung cancer (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Phylogeographie (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Supportivtherapie (2)
- T‑DM1 (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- guideline (2)
- kidney (2)
- local recurrence (2)
- neoadjuvant therapy (2)
- neoadjuvante Therapie (2)
- phylogeography (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- survival (2)
- treatment/therapy (2)
- 1,2-Dimesitoylbenzene (1)
- ADAMTS-13 (1)
- AM1 Calculations (1)
- AML (1)
- Advanced breast cancer (1)
- Alzheimer’s dementia (1)
- Amyloid-beta 42 (1)
- Animal models (1)
- Anti-kaon–nucleon physics (1)
- Antihormone therapy (1)
- Automata theory (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- Baryonic resonances (1)
- Benthos (1)
- Biodiversität (1)
- Biotin (1)
- Blocked occlusion (1)
- Body sway (1)
- CAI-1 (1)
- CRISPR/Cas (1)
- Carrier-bound fibrin sealant (1)
- Causality assessment (1)
- Clinical Trials and Observations (1)
- Clinical trial (1)
- Cohort studies (1)
- Collagen hemostat (1)
- Council for International Organizations of Medical Sciences (1)
- Crystal Structure (1)
- Crystal structure (1)
- Cyanine Distortion (1)
- Dehydrogenase Cofactors (1)
- Direct carbon (1)
- Diversity (1)
- Duganella (1)
- EP300 (1)
- ESR Spectra (1)
- EWSR1 (1)
- Effective half-life (1)
- Electron Transfer (1)
- Electron-pion identification (1)
- Electronic Structure (1)
- Entomology (1)
- Esters (1)
- Eukaryota (1)
- Expedition Brochure (1)
- Expeditionsbericht (1)
- FAPI PET (1)
- FOXO1 (1)
- Fibre/foam sandwich radiator (1)
- Freezeout (1)
- Fusarium graminearum (1)
- G-protein-coupled receptor (1)
- Gene fusion (1)
- Genome editing (1)
- Graves’ disease (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- Heavy ion storage ring (1)
- Heavy-ion reactions (1)
- Hemostatics (1)
- Herb induced liver injury (1)
- Herbs (1)
- Heregulin (1)
- High-pressure (1)
- Hippocampal volume (1)
- Hyperconjugation (1)
- Hypofractionated radiotherapy (1)
- Immunomonitoring (1)
- Infinite games with perfect information (1)
- Internal ribosome entry site (1)
- Ionisation energy loss (1)
- Isolierung (1)
- Janthinobacterium (1)
- Kaonic nuclei (1)
- Labordiagnose (1)
- Lebensgemeinschaft (1)
- Liver resection (1)
- Low energy QCD (1)
- Luciferase (1)
- MM-121 (1)
- MNDO Calculations (1)
- Meersseman test (1)
- Meloneta alpica (1)
- Metastatic (1)
- Mild cognitive impairment (1)
- Molecular Conformation (1)
- Molecular diagnostic testing (1)
- Multi-wire proportional drift chamber (1)
- Multianvil (1)
- Myeloid Neoplasia (1)
- Neural network (1)
- Neuroepithelial tumor (1)
- Orbital electron capture (1)
- Organosilicon Compounds (1)
- Orthopaedics (1)
- Oxidation States (1)
- Oxo-and Alkylamino-Substituted p-Benzoquinone Derivatives (1)
- PAGE (1)
- PCR (1)
- PLAGL1 (1)
- Partial wave analysis (1)
- Phospho-tau (1)
- Phosphorylation (1)
- Phylogenetik (1)
- Phylogenomics (1)
- Pityogenes (1)
- Population genetics (1)
- Prediction (1)
- Protein translation (1)
- RNA (1)
- RNActive (1)
- Radical Anion Sodium Salt (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Randomized controlled trial (1)
- Rare-earth borate (1)
- Re-exposure (1)
- Registries (1)
- Ruthenium Complexes (1)
- SSCP (1)
- Scolytidae (1)
- Scolytinae (1)
- Seribantumab (1)
- Single Crystal Structures (1)
- Single particle decay spectroscopy (1)
- Substituent Effects (1)
- Supratentorial (1)
- Symmetrical blocked occlusion (1)
- T-DM1 (1)
- TLR2/6 (1)
- TR (1)
- Tau (1)
- Terbium (1)
- Thyroid (1)
- Tracking (1)
- Transition radiation detector (1)
- Translation initiation (1)
- Translational research (1)
- Trigger (1)
- Two body weak decay (1)
- Upper body posture (1)
- VARGADO (1)
- Videorasterstereography (1)
- Water balance (1)
- Weight distribution (1)
- Xenon-based gas mixture (1)
- Zellkultur (1)
- Zooplankton (1)
- acute myeloid leukemia (1)
- advanced breast cancer (1)
- algorithms (1)
- allocation (1)
- angio-immunogenic switch (1)
- antihormone therapy (1)
- available water capacity (1)
- bacterium-fungus interaction (1)
- benthic communities (1)
- biodiversity (1)
- biogenic amine (1)
- bleeding (1)
- blood flow recovery (1)
- bortezomib (1)
- cell culture (1)
- cellular signaling (1)
- chemical vapour deposition (1)
- chemotherapy (1)
- child (1)
- collateral growth (1)
- combinatorics (1)
- dE/dx (1)
- data structures (1)
- denervation (1)
- detection (1)
- docetaxel (1)
- dopamine (1)
- drought-stress (1)
- dwarf-shrub heath (1)
- femoral artery ligation (1)
- fibrosis imaging (1)
- field-effect transistor (1)
- forest (1)
- forest site classification (1)
- fourth (1)
- graft (1)
- habitat boundary (1)
- hierarchies and reducibilities (1)
- induction chemotherapy (1)
- induction regimen (1)
- insect (1)
- interleukin-6 (1)
- intracranial hemorrhage (1)
- isolation (1)
- laboratory diagnosis (1)
- lapatinib (1)
- lenalidomide (1)
- local radiotherapy (1)
- logic (1)
- loss (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- metastasis (1)
- mitochondrial DNA (1)
- mitochondriale DNA (1)
- mtDNA (1)
- multiple myeloma (1)
- nintedanib (1)
- non-small cell lung cancer (1)
- non-small-cell lung cancer (1)
- nuclear cardiology (1)
- oligosilanes (1)
- pertuzumab (1)
- phylogenetics (1)
- platelet substitution (1)
- ppK − (1)
- proteomics (1)
- pulmonary hypertension (1)
- quorum sensing (1)
- radiation (1)
- radiation-induced nanostructures (1)
- re-transplantation (1)
- reactive systems (1)
- renal failure (1)
- repeated (1)
- respiratorische Infektion (1)
- respiratory infection (1)
- risk stratification (1)
- salivary gland (1)
- silicon nanowires (1)
- site classification system (1)
- small proteins (1)
- specification and verification (1)
- structural biology (1)
- structure–activity relationships (1)
- third (1)
- thrombotic microangiopathy (1)
- thrombotic thrombocytopenic purpura (1)
- trastuzumab (1)
- tumor microenvironment (1)
- vapor–liquid–solid mechanism (1)
- vascular surgery (1)
- verification (1)
- violacein (1)
- von Willebrand factor (1)
- zooplankton (1)
- α-Iminoketones (1)
Institute
Update Mammakarzinom 2018 (Teil 2) – fortgeschrittenes Mammakarzinom, Lebensqualität und Prävention
(2018)
Die Behandlung des metastasierten Mammakarzinoms hat bei immer neu zu testenden Therapien deutlich an Komplexität zugenommen. Therapien werden nunmehr nur noch für spezielle klinische oder molekulare Subgruppen entwickelt. Hierbei spielen die intrinsischen, molekularen Subtypen zwar immer noch die größte Rolle, jedoch gibt es zunehmend auch Therapien, die subgruppen- oder sogar histologieübergreifend entwickelt werden, wie z. B. der PARP-Inhibitor bei BRCA-mutierten Patientinnen (Mamma- und Ovarialkarzinom). Aber auch Supportivtherapien entwickeln sich weiter, sodass Probleme wie die Alopezie besser behandelt werden können und neue Therapiearten von Übelkeit und Erbrechen etabliert werden. In einem engen Zusammenhang mit den Supportivtherapien stehen die Nebenwirkungen, welche bei Patientinnen mit einem metastasierten Mammakarzinom einen direkten Einfluss auf die Prognose haben. Hier könnten digitale Werkzeuge helfen, um ein besseres Patientinnenmanagement zu etablieren. Diese Übersichtsarbeit soll diese Aspekte vor dem Hintergrund neuer, aktuell publizierter Studien beleuchten und einen Einblick geben, wie sich diese Studien zu etablierten Routinetherapien verhalten. Zusätzlich werden aktuelle Aspekte der Mammakarzinomprävention beleuchtet.
Beim primären, frühen Mammakarzinom zielt die Behandlungsplanung auf ein immer besseres Verständnis der Erkrankung ab. Die Identifikation von Patientinnen mit einer exzellenten Prognose könnte dieser Gruppe helfen, unnötige Therapien zu vermeiden. Weiterhin wird die Planung der Therapie immer weiter auf die Patientin abgestimmt. Das Wissen über Patientinnen, die besonders von einer Chemotherapie profitieren, wächst genauso wie das Wissen um Patientinnen, die von einer Immuntherapie profitieren könnten. Hinsichtlich der Immuntherapien stehen die durchgeführten Studien kurz vor der Publikation. Einzelne kleinere Studien bieten einen ersten Einblick in die Wirksamkeit der Checkpoint-Inhibitoren (Anti-PD1/PDL1-Therapien). Nicht zuletzt konnte kürzlich eine der größten Brustkrebsstudien aller Zeiten zu Ende geführt werden. Die Anwendung eines Multigentests konnte zeigen, dass er ausreicht, um Patientinnen mit einer so guten Prognose zu identifizieren, dass keine Chemotherapie nötig ist. Dieser Review-Artikel soll die aktuellen Studien zusammenfassen und einen Ausblick der gegenwärtigen Entwicklungen geben.
For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.
The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes play a major role, more and more new therapies for subgroups and histological subtypes are being developed, such as the use of PARP inhibitors to treat patients with BRCA mutations (breast and ovarian cancer). Supportive therapies are also evolving, allowing problems such as alopecia or nausea and vomiting to be treated more effectively. Treatment-related side effects have a direct impact on the prognosis of patients with metastatic breast cancer, and supportive therapy can improve compliance. Digital tools could be useful to establish better patient management systems. This overview provides an insight into recent trials and how the findings could affect routine treatment. Current aspects of breast cancer prevention are also presented.
In primary early breast cancer, the aim of treatment planning is to obtain an increasingly better understanding of the disease. The identification of patients with an excellent prognosis could help this group avoid unnecessary treatments. Furthermore, the planning of treatment is becoming increasingly patient-focussed. There is a growing understanding of those patients who benefit particularly from chemotherapy, as well as of those who could benefit from immunotherapy. Studies conducted on immunotherapies will be published shortly. Smaller individual studies offer an initial insight into the efficacy of checkpoint inhibitors (anti-PD1/PDL1 therapies). Not least, one of the largest breast cancer studies of all times has recently come to an end. The use of a multigene test has shown that it is sufficient to identify patients with such a good prognosis that chemotherapy is unnecessary. This review article is intended to summarise the current studies and give an outlook on current developments.
In dieser Übersichtsarbeit wird dargestellt, wie neue Therapien oder neue Aspekte etablierter Therapien in Zusammenhang mit neuesten, aktuellen Erkenntnissen stehen. Neoadjuvanz, Lokaltherapie, neue Aspekte der Systemtherapie und Prognose- sowie Prädiktivfaktoren werden beleuchtet. In der Neoadjuvanz ist nach wie vor der Zusammenhang zwischen pCR und Prognose von Interesse, ebenso wie neue molekulare Prädiktoren für neue Therapien wie CDK4/6-Inhibitoren zu identifizieren. Bei der operativen Behandlung wird weiter nach einer Reduktion der Aggressivität gestrebt. Insbesondere das duktale Carcinoma in situ muss dafür noch besser verstanden werden. Bei den Systemtherapien wächst die Datenlage zum Verständnis der besten Kombinationen und Therapieabläufe für bestehende Therapieverfahren. Letztendlich muss mithilfe von Prognose- und Prädiktivfaktoren vermieden werden, dass Übertherapien stattfinden und nur die Patientin spezifische Therapien erhält, welche bei dieser individuellen Patientin eine nachgewiesene Wirksamkeit mit wenig Nebenwirkungen haben.
The structures of seven di- or tetrasubstituted p-benzoquinone derivatives O=C(XC=CH )2C=O and O=C(XC=CX)2C=O with substituents X = -OCH3, -N(CH2)5, - N(CH2CH2)2O, -Cl, -CN and -⊕N(HC=CH)2C-N(CH3)2 are presented and discussed in comparison with published ones substituted by X = -Si(CH3)3, -C6H5, -N(CH3)2, -⊕N(HC=CH)2CN(CH3)2, -O⊖ , and - NO2. Based on the introduction, in which halfwave-reduction potentials, geometry-optimized quantum-chemical calculations on substituent perturbation and known structural data of p-benzoquinone derivatives are used to characterize their molecular ground states. The structural changes indicate how substituent perturbations might be rationalized. Of the categories defined - imperturbed, donor, donor/acceptor and acceptor perturbed - the donorsubstituted p-benzoquinones do exhibit the largest differences, often called cyanine distorsion. In very satisfactory agreement with extensive semiempirical calculations, all effects determined experimentally are discussed in terms of varying charge distribution. With respect to the biochemical importance of p-benzoquinone derivatives, this first structural summary points out important facets.
Chelate complexes of 1,2-dimesitoylbenzene radical anion with alkali metal cations exhibit in aprotic solution extremely large ESR /ENDOR metal coupling constants. For rationalization, structures of both the neutral molecule (H3C)3H2C6 - CO - C6H4 - CO - C6H2(CH3)3, in which the two carbonyl groups are twisted out of the benzene ring plane by dihedral angles of ± 3̄7̄°, and a sodium contact ion quadruple have been determined. One of the dimers [dimesitoylbenzeneH⊖ (Na⊕H2N H2C - CH2NH2)]2, although generated by Na metal mirror reduction of 1,2-dimesitoylbenzene in aprotic DME solution with added ethylendiamine for better electron transfer, surprisingly contains two 245 pm short (!) hydrogen bridges ⊖O ··· (H)O and in addition two solvation bridges e ⊖O ··· Na⊕(H2NH2C - CH2NH2) ··· O⊖. Results of MNDO calculations based on the experimental coordinates support the proposed concept.
The Compressed Baryonic Matter (CBM) experiment is a dedicated heavy ion collision experiment at the FAIR facility. It will be one of the first HEP experiments which works in a triggerless mode: data received in the DAQ from the detectors will not be associated with events by a hardware trigger anymore. All raw data within a giventime period will be collected continuously in containers, so-called time-slices. The task of the reconstruction algorithms is to create events out of this raw data stream. In this contribution, the optimization of the reconstruction software in the RICH detector to the free-streaming data flow is presented. The implementation of ring reconstruction algorithms which use time measurements of the hits as an additional parameter is discussed.
Memory Concerns, Memory Performance and Risk of Dementia in Patients with Mild Cognitive Impairment
(2014)
Background: Concerns about worsening memory (“memory concerns”; MC) and impairment in memory performance are both predictors of Alzheimer's dementia (AD). The relationship of both in dementia prediction at the pre-dementia disease stage, however, is not well explored. Refined understanding of the contribution of both MC and memory performance in dementia prediction is crucial for defining at-risk populations. We examined the risk of incident AD by MC and memory performance in patients with mild cognitive impairment (MCI).
Methods: We analyzed data of 417 MCI patients from a longitudinal multicenter observational study. Patients were classified based on presence (n = 305) vs. absence (n = 112) of MC. Risk of incident AD was estimated with Cox Proportional-Hazards regression models.
Results: Risk of incident AD was increased by MC (HR = 2.55, 95%CI: 1.33–4.89), lower memory performance (HR = 0.63, 95%CI: 0.56–0.71) and ApoE4-genotype (HR = 1.89, 95%CI: 1.18–3.02). An interaction effect between MC and memory performance was observed. The predictive power of MC was greatest for patients with very mild memory impairment and decreased with increasing memory impairment.
Conclusions: Our data suggest that the power of MC as a predictor of future dementia at the MCI stage varies with the patients' level of cognitive impairment. While MC are predictive at early stage MCI, their predictive value at more advanced stages of MCI is reduced. This suggests that loss of insight related to AD may occur at the late stage of MCI.